Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting (NANOM PCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01436123
Recruitment Status : Terminated (The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology)
First Posted : September 19, 2011
Last Update Posted : May 19, 2015
Ural Institute of Cardiology
De Haar Research Foundation
Ural Federal University
Information provided by (Responsible Party):
Alexander Kharlamov, Ural Medical University

Brief Summary:

Intensive therapy with rosuvastatin 40 mg and ApoA-I Milano reduces the total atheroma volume (TAV) up to 6.38 or 14.1 mm3 respectively. Our previous bench studies PLASMONICS and NANOM First-in-Man trial documented TAV reduction up to unprecedented 79.4 and 60.3 mm3 respectively with high level of safety and feasibility.

The completed randomized two arm (1:1) study (NANOM-PCI) with parallel assignment (n=62) assessed (NCT01436123) the safety and feasibility of the delivery technique for nanoparticles (NP) using micro-injection catheter (with intravascular intramural injection of allogeneous stem cells carrying NP after MSCT-, IVUS- and OCT-guided mapping of the vessel), and plasmonic photothermal therapy of atherosclerosis combined with stenting (Nano group, n=32) versus stenting with Xience V cage (Stenting group, n=30). The primary outcome was TAV at 12 months.

The mean reduction of TAV at 12 months in Nano group was -84.1 mm3 (95% CI: SD 28.3; min -52.4 mm3, max -99.1 mm3; p<0.05) versus +12.4 mm3 in case of stenting (p<0.05 between groups). 42/62 patients (68%) in Nano group passed the Glagov threshold of a 40% plaque burden with mean plaque burden (PB) 36.2% (95% CI: SD 9.3%, min 30.9%, max 44.5%). The increase of the minimal lumen diameter was 61.2 and 63.3% at 12 month follow up in groups respectively. The serial assessment of VH-IVUS showed a significant decrease at 12 months in the dense calcium area, fibrous and fibro-fatty tissue with fulminant necrosis due to thermolysis in Nano-group, whereas an increase of fibrous and fibro-fatty components in stenting arm. We have documented 2 vs 3 cases of the definite thrombosis and 3 vs 5 cases of target lesion revascularization in groups respectively. The analysis of the event-free survival of the ongoing clinical follow-up shows the significantly lower risk of cardiovascular death in Nano group if compare with conventional stenting (93.4% vs 86.7%; p<0.05).

Plasmonic resonance-mediated therapy using noble-metal NP associated with significant regression of coronary atherosclerosis. Tested delivery approach has acceptable safety and efficacy for atheroregression below a 40% PB.

The investigators hypothesize that multistep approach with the use of stent in acute care unit, and then subsequent transcatheter micro-injection with nanoparticles can resolve atherosclerosis, stop and regress atherogenesis, remodulate or even rejuvenate arteries. Stem cells in patch can be good carriers for nanoparticles as well as high-effective metabolic vectors (paracrine-like regulation of alive cells and via bioactive products of cell lysis after detonation of nanoparticles) for the treatment of plaque on site. Gold nanoparticles with silica-iron oxide shells promise high-energy plasmonic photothermic burning or melting effect under the near-infrared laser irradiation onto the lesion. Thus the investigators expect complex two-side effect on the plaque with protected lumen and adventitia.

Novel discoveries in atherogenesis, and development of nanobiotechnologies with potentials for the management of atherosclerosis leads us to the quest of new approaches. The investigators still cannot really effectively treat atherosclerosis.

The investigators management is more symptomatic, and lipid-pool or inflammation-oriented! The investigators cannot manage non-organic part (mineral deposits, calcified necrotic core, partially collagen and fibrotic tissue) and total plaque volume Surgery and invasive procedures is just focused on blood flow restoration (just manipulate the form of plaque) + concerns of clinical and technical restrictions (incl. alien body - stent) + risk of restenosis or subacute 'fatal' in-stent atherothrombosis + graft survival/ occlusion + surgery-related complications High rate of short- and long-term complications and readmissions. Regression of atherosclerosis in fact is still a dream. The investigators offer an alternative to stenting and may be cardiac artery bypass surgery (CABG). Our approach can really allow to rejuvenate arteries, Plasmonic photothermal therapy (PPTT) can burn plaque, but stem cells and bioengineered structures promise restoration of the vessel wall.

Our personal previous data showed that PPTT can 1.6-fold reduce a volume of plaque with most optimal long-term result in subsets with the use of SPCs as a delivery approach. The most optimal delivery systems of NPs into the plaque are the on-artery bioengineered patch and ferro-magnetic approach.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Atherosclerosis Other: Stenting and micro-infusion of NP Device: Implantation of everolimus-eluting stent Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis With The Use of Gold Nanoparticles With Iron Oxide-Silica Shells Versus Stenting
Study Start Date : December 2010
Actual Primary Completion Date : July 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis Iron
Drug Information available for: Everolimus

Arm Intervention/treatment
Experimental: Stenting + Micro-infusion
Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
Other: Stenting and micro-infusion of NP
Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
Other Names:
  • Plasmonic Photothermal Therapy (PPTT)
  • Stem cell therapy
  • Bioengineering
  • Stenting
  • Xience V stent

Active Comparator: Stenting
Put in everolimus-eluting stent
Device: Implantation of everolimus-eluting stent
Put stent in ischemia-related coronary artery by indications for PCI
Other Names:
  • Stenting
  • Xience V stent

Primary Outcome Measures :
  1. Total atheroma volume [ Time Frame: at month 12 ]
    Total plaque volume measured by intravascular ultrasound (IVUS), cubic mm.

Secondary Outcome Measures :
  1. Composite end-point of any MACE (major acute cardiovascular events), all-cause death, any revascularization [ Time Frame: at month 12 ]
    Composite end-point of all-cause death, all MACE - major cardiovascular events, any revascularization

  2. Composition of plaque [ Time Frame: at month 12 ]
    Analysis of IVUS(intravascular ultrasound)-related composition of plaque (calcified deposits, necrotic calcified core), fibro-lipid core and etc.

  3. Major and minor bleeding [ Time Frame: at month 12 ]
    Clinical examination of major and minor bleeding under the antithrombotic therapy

  4. Restenosis rate [ Time Frame: at month 12 ]
    Restenosis rate verified clinically + IVUS

  5. Stent thrombosis rate [ Time Frame: at month 12 ]
    Stent thrombosis rate verified clinically, angiography, IVUS

  6. Coronary flow-mediated vasodilatation [ Time Frame: at month 12 ]
    Ultrasound-related examination of coronary flow-mediated vasodilatation

  7. Coronary intima-media thickness [ Time Frame: at month 12 ]
    Ultrasound-IVUS-related examination of coronary intima-media thickness

  8. Minimum diameter stenosis [ Time Frame: at month 12 ]
    IVUS-related assessment of minimum diameter stenosis

  9. Minimum lumen diameter [ Time Frame: at month 12 ]
    IVUS-related assessment of minimum lumen diameter

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Multivessel coronary artery disease without indications for CABG
  • Stable angina with indications for preventive PCI
  • NSTEMI (primary PCI and late comers) <=> 12 hr
  • STEMI with kept EF>50% (all comers)
  • Rescue PCI
  • Vessel size between 2.3-4.0 mm
  • NYHA II-III functional class of HF
  • De novo treatment = no history of PCI or CABG
  • Atherosclerosis of proximal left anterior descending artery <50% stenosis
  • Treated hypertension
  • Signed written informed consent

Exclusion Criteria:

  • History of MI
  • History of CABG or PCI
  • Indications for CABG
  • Contraindications for CABG, PCI
  • History of unstable angina, coronary artery syndrome
  • History of arrhythmias
  • History of stroke
  • NYHA I, IV functional class of HF
  • Diabetes (fasting glucose > 7.0 mM/L)
  • Untreated hypertension
  • Asthma
  • Participation to any drug-investigations during previous 60 days
  • Pregnancy
  • Intolerance to any limus drugs, aspirin, clopidogrel, aspirin, metals and polymers of stent and nanoparticles
  • Need for chronic treatment with anti-vitamin K drugs
  • Impossibility of clinical follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01436123

De Haar Research Foundation
Rotterdam, South Holland, Netherlands, 3071PR
Russian Federation
Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University
Yekaterinburg, Sverdlovsk oblast, Russian Federation, 620000
Ural Institute of Cardiology
Yekaterinburg, Sverdlovsk oblast, Russian Federation, 620144
Sponsors and Collaborators
Ural Medical University
Ural Institute of Cardiology
De Haar Research Foundation
Ural Federal University
Principal Investigator: Alexander Kharlamov, M.D., Ph.D. Ural Institute of Cardiology
Study Chair: Jan Gabinsky, M.D., Ph.D. Ural Institute of Cardiology
Study Director: Olga Kovtun, M.D., Ph.D. Ural Medical University

Additional Information:
Responsible Party: Alexander Kharlamov, Research manager, Ural Medical University Identifier: NCT01436123     History of Changes
Other Study ID Numbers: NANOM PCI
First Posted: September 19, 2011    Key Record Dates
Last Update Posted: May 19, 2015
Last Verified: May 2015

Keywords provided by Alexander Kharlamov, Ural Medical University:
Plasmonic Photothermal Therapy
Stem cells
Biodegradable stenting
Repair disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents